Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute for Clinical Genetics, |
RCV001868796 | SCV002010244 | uncertain significance | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001868796 | SCV002268010 | uncertain significance | not provided | 2023-06-15 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 517 of the ERCC3 protein (p.Glu517Lys). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ERCC3 protein function. ClinVar contains an entry for this variant (Variation ID: 1319554). This variant has not been reported in the literature in individuals affected with ERCC3-related conditions. This variant is present in population databases (rs781202683, gnomAD 0.04%). |
Sema4, |
RCV002256834 | SCV002532606 | uncertain significance | Xeroderma pigmentosum | 2021-10-02 | criteria provided, single submitter | curation |